Thyroid cancer

AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer

Retrieved on: 
木曜日, 5月 23, 2024
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Survival, MD Anderson Cancer Center, Britz, MCR, University, Therapy, Disease, Safety, Cytokine release syndrome, Assistant, Efficacy, Incidence, ATC, ASCO, DLS, Thyroid cancer, Anaplastic thyroid cancer, ADTC, PDTC, DCR, CRS

Notably, a metabolic complete response (mCR) was achieved in one patient with anaplastic thyroid cancer (ATC), the most aggressive form of the disease.

Key Points: 
  • Notably, a metabolic complete response (mCR) was achieved in one patient with anaplastic thyroid cancer (ATC), the most aggressive form of the disease.
  • “We are excited to be the first to demonstrate the potential of autologous CAR T to induce a complete response in a patient with a solid tumor cancer.
  • The confirmed mCR in the AIC100 Phase 1 study is the first known complete response following a single IV dose of autologous CAR T cells observed in any solid tumor cancer type,” said Matt Britz, CEO, AffyImmune.
  • These are aggressive forms of thyroid cancer that currently have limited treatment options and poor patient outcomes.

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

Retrieved on: 
水曜日, 5月 22, 2024
Software, Biotechnology, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Genetics, ENDO, Endocrine Society, Intelligence, Thyroid cancer, Exhibition, Disease, Endocrinology, Thyroid, Pharmaceutical industry

The findings will be presented at ENDO 2024, the annual meeting of The Endocrine Society, which will take place June 1-4 in Boston.

Key Points: 
  • The findings will be presented at ENDO 2024, the annual meeting of The Endocrine Society, which will take place June 1-4 in Boston.
  • “Molecular testing in thyroid cancer currently focuses primarily on whether a patient’s thyroid nodule is benign or cancerous, and whether specific gene mutations are present,” said Joshua Klopper, M.D., Veracyte’s medical director for Endocrinology.
  • “The data to be presented at ENDO 2024 looks beyond individual gene mutations and explores the potential of novel molecular signatures and alterations to provide more-granular, prognostic information.
  • This may ultimately help clinicians guide more individualized care based on the molecular characteristics of each patient’s tumor.

Foundation Medicine Launches RNA Sequencing Test, FoundationOne®RNA, in the U.S.

Retrieved on: 
火曜日, 5月 21, 2024
Medical Supplies, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Genetics, Science, Patient, DNA, Bone marrow, Bladder cancer, Tracker, Lung cancer, Neoplasm, Liquid, NSCLC, Heme, Cholangiocarcinoma, MD, Blood, Pancreatic cancer, Cancer, Gene, Foundation Medicine, Sarcoma, RNA, Thyroid cancer, Physician, Monitor, Vaccine

Foundation Medicine, Inc. , today announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes.

Key Points: 
  • Foundation Medicine, Inc. , today announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes.
  • Foundation Medicine also offers circulating tumor DNA monitoring assays, including clinically available and tissue-informed FoundationOne®Tracker, and tissue-naïve FoundationOne®Monitor, which is currently available for research use.
  • “While DNA sequencing with optimized targeting using FoundationOne CDx can detect many fusions, RNA sequencing with FoundationOne RNA can provide another layer of sophisticated fusion detection in 318 genes,” says Mia Levy, MD, PhD, Chief Medical Officer, Foundation Medicine.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

ICPO Foundation awards ICPO Academy stipends to the Department of Nuclear Medicine at Osaka University Hospital

Retrieved on: 
月曜日, 5月 6, 2024
Pillar, PET-CT, Nuclear medicine, Research, Clinic, Curriculum, Medical physics, Nursing, Osaka University Hospital, Principal, ICPO, FAPI, Radiochemistry, Osaka University, Teaching hospital, Thyroid cancer, Health, Associate, Acid test (gold)

Today, the International Centers for Precision Oncology (ICPO) Foundation announced a cooperation with the Department of Nuclear Medicine at the Osaka University Hospital.

Key Points: 
  • Today, the International Centers for Precision Oncology (ICPO) Foundation announced a cooperation with the Department of Nuclear Medicine at the Osaka University Hospital.
  • ICPO offers industry-funded stipends for the ICPO Academy for Theranostics to dedicated healthcare professionals worldwide.
  • "Through this agreement, we have the opportunity to provide advanced training in theranostics to team members of the Department for Nuclear Medicine at Osaka University Hospital.
  • Osaka University Hospital, known for its dedication to excellence, places significant emphasis on research and development in the medical field.

Global $46.7B Cancer Biomarkers Market Outlook, 2035: MET Biomarkers Lead the Charge, Driven by Rising Incidence of Lung Cancer and Drug Development - ResearchAndMarkets.com

Retrieved on: 
水曜日, 5月 8, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Foundation Medicine, MSI, Lung cancer, Breast cancer, Blood, AI, MDPI, Skin cancer, Agilent Technologies, Prostate cancer, Biomarker, ALK, Kidney cancer, EGFR, OncoDNA, Cancer, Bladder cancer, Tempus, Son, Non-small-cell lung cancer, Frontiers Media, HER2, Colorectal cancer, Turbine, Thyroid cancer, ARUP Laboratories, Roche, Database, Therapy, Merck, NSCLC, Thermo Fisher Scientific, Nature, Publication, Laboratory, Survival, Insurance, BioMed Central, Nature Portfolio, Incidence, Drug development, Liver cancer, Liquid biopsy, MET, NTRK, CK Life Sciences, Endometrial cancer, Actuate, PD-L1, Patient, Gastrointestinal cancer, Physician, Neoplasm, Head, Medical imaging

Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.

Key Points: 
  • Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.
  • Currently, the market is driven by breast cancer biomarkers and lung cancer biomarkers; however, in the coming future, we anticipate cancer biomarker market for leukemia to grow at a significant pace.
  • The market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the cancer biomarkers market.
  • It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.

Jennifer Grey to be Honored for Her Cancer Advocacy, Along with Chief Strategy & Marketing Officer for GE Healthcare Andy DeLaO and Renowned Cancer Physician-Scientist Dr. Antoni Ribas at Tower Cancer Research Foundation's 22nd Annual Tower of Hope Gala i

Retrieved on: 
月曜日, 5月 6, 2024
FDA, Physics, Breast cancer, Searchlight Pictures, Wish You Were Here, Doctor of Philosophy, Politics, Medicine, Trametinib, Thyroid cancer, Season, ALL, UCLA, Cancer, Infant, Corner, Breast Cancer Research, Jonsson Comprehensive Cancer Center, Dirty Dancing, Ferris Bueller's Day Off, Sundance Film Festival, Vemurafenib, Dream, GE HealthCare, Research, MEK, BRAF, Work, Melanoma, Pembrolizumab, Tower Cancer Research Foundation, Pharmacology, University, American College, Hope, MD, Patient, De la O, Disease, Beverly Wilshire Hotel, Best Actress, Lionsgate, Cobimetinib, Radiation

The event begins at 6:00 PM at the Beverly Wilshire, A Four Seasons Hotel, 9500 Wilshire Boulevard in Beverly Hills, California.

Key Points: 
  • The event begins at 6:00 PM at the Beverly Wilshire, A Four Seasons Hotel, 9500 Wilshire Boulevard in Beverly Hills, California.
  • She most recently wrapped production on Julia Stiles' directorial debut for Lionsgate, "Wish You Were Here," opposite Kelsey Grammer.
  • DeLaO is the Chief Strategy & Marketing Officer for GE Healthcare's business focused on building care at the n-of-1 using the diagnostic gateway to precision health and care.
  • He is affiliated with multiple international cancer research associations, and is a past president of the American Association for Cancer Research.

AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC

Retrieved on: 
火曜日, 3月 19, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, CALD, Control, Thyroid cancer, Growth, Bluebird bio, MAA, Drug discovery, Business, MIT, Britz, Patient, SVP, Marketing Authorisation Application, Merck, MSAT, Business development, Acquisition, CMC, Betibeglogene autotemcel, Technology transfer, Senior, MBA, CMCF, Therapy, Takeda, Equinox Group, Dana–Farber Cancer Institute, Multimedia, Chemical engineering, DFCI, Partnership, Biology, BLA, Pharmaceutical industry

AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.

Key Points: 
  • AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.
  • Matt is well-suited to lead AffyImmune as CEO as the Company accelerates clinical development of AIC100 in thyroid cancer, and in other indications with high unmet medical need.
  • Matt Britz joined AffyImmune in June 2021 as Senior Vice President (SVP), Business Development and was promoted to Chief Operating Officer in January 2022.
  • Pete Gelinas brings over 15 years of extensive experience in Manufacturing and CMC Product Development to AffyImmune.

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR FISCAL YEAR 2023

Retrieved on: 
月曜日, 4月 1, 2024
Medical device, Thyroid cancer, Growth, The Twelve Months, Third party, Calibration, Sale, IDAHO, Intellectual property, I-131, OTCQB, Nuclear medicine, Cryptocurrency

IDAHO FALLS, Idaho, April 1, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the twelve-month periods ended December 31, 2023.

Key Points: 
  • IDAHO FALLS, Idaho, April 1, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the twelve-month periods ended December 31, 2023.
  • Revenue for the twelve months ended December 31, 2023, was $12.3 million compared to $11.2 million for the same period in 2022.
  • As of December 31, 2023, cash and cash equivalents improved to $2.7 million compared to $2.4 million as of December 31, 2022.
  • Shahe Bagerdjian, President & CEO of the Company, said, "The 2023 fiscal results are very encouraging; we posted the highest revenue in the company's history, and the company had positive cash flow from operating activities.

Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Retrieved on: 
水曜日, 4月 3, 2024
Community, Eurostat, Civil service commission, Thyroid cancer, Diagnosis, Metabolism, Diarrhea, Enzyme, Hormone, Growth, Thyroid hormones, Prevalence, Cell, Calcitonin, Disease, Patient, Malignancy, Committee, Knowledge, Tissue, Seriousness, Doxorubicin, Boulogne-Billancourt, Regulation, Cancer, EMA, IRIS, Thyroid neoplasm, Cabozantinib, Protein, Medullary thyroid cancer, Thyroid, European, COMP, Iodine, European Commission, Safety, Blood, Marketing, Human, Pharmaceutical industry

Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Key Points: 


Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Retrieved on: 
金曜日, 3月 8, 2024
Gastroesophageal reflux disease, Research, Heartburn, Blood, Diet, Cholesterol, Dietary supplement, Obesity, Dizziness, Pancreatitis, Vomiting, Health care, History, Thyroid cancer, Fatigue, Hypoglycemia, Acute kidney injury, Depression, Patient, Kidney disease, Abdominal distension, Burping, Cosmetics, Cardiovascular disease, Suicide, Weight, Stroke, Nausea, Diabetic retinopathy, Pancreas, Insulin, Blood pressure, Multimedia, Overweight, Diarrhea, Novo Nordisk, Vaccine, Safety, Heated tobacco product, Indigestion, Heart, Human services, Priority review, Division, Headache, Inflammation, FDA, Food, Weight loss, Thought, Heart rate, Gallstone, Risk, Animal, Allergy, Constipation, Death, Flatulence, Public

"This patient population has a higher risk of cardiovascular death, heart attack and stroke.

Key Points: 
  • "This patient population has a higher risk of cardiovascular death, heart attack and stroke.
  • Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
  • Obesity or overweight affect approximately 70% of American adults.
  • Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.